<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00772304</url>
  </required_header>
  <id_info>
    <org_study_id>SMA-08-21</org_study_id>
    <nct_id>NCT00772304</nct_id>
  </id_info>
  <brief_title>Evaluation of the Sensory Attributes of Olopatadine 0.6% and Azelastine 137mcg Nasal Sprays in Patients w/Allergic Rhinitis</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Alcon Research</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Alcon Research</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To compare patient perceptions of the sensory attributes, including taste and aftertaste, of
      Olopatadine relative to azelastine when administered as a single dose in patients with
      allergic rhinitis.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2008</start_date>
  <primary_completion_date type="Actual">November 2008</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Product Preference Questionnaire for Immediate Taste</measure>
    <time_frame>5 min post-dose</time_frame>
    <description>Using a set of coded responses, subjects evaluated product preference in regards to immediate taste</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Taste and Aftertaste of Medication</measure>
    <time_frame>5 min, 45 min.</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">102</enrollment>
  <condition>Allergic Rhinitis</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Olopatadine 0.6% / Azelastine 137 mcg</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Olopatadine 0.6% / Azelastine 137 mcg</intervention_name>
    <description>single dose; 2 sprays per nostril</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Must have a history (at least 2 yrs) of allergic rhinitis and be symptomatic at time
             of enrollment

          2. 18 yrs of age or older

          3. Read and sign informed consent

          4. Females of childbearing potential may participate if: are non-breast feeding, have
             negative urine pregnancy test at visit 1, agree to take urine pregnancy test upon
             exiting study, do not intend to become pregnant during the study, are using adequate
             methods of birth control.

        Exclusion Criteria:

          1. History of intolerance or hypersensitivity to any component of the study medications,
             including benzalkonium chloride.

          2. Any disease or systemic disorder that may complicate or interfere with investigation
             or evaluation of the study medications (including but not limited to): Rhinitis
             medicamentosa, large obstructive nasal polyps, history (w/in last 3 months) of nasal
             septic ulcers, nasal surgery or nasal trauma, history or evidence of nasolacrimal
             drainage system malfunction, history (w/in 30 days) or evidence of sinusitis or upper
             or lower respiratory infection.

          3. Impairment of sense of tast or smell (self reported)

          4. Asthma, except for mild, intermittent asthma (nat'l Asthma guidelines)

          5. Congestion, that in the opinion of the investigator, that would interfere with
             successful nasal drug administration/absorption

          6. Patients w/a severe impairment of nasal breathing

          7. Anatomic abnormalities of as identified by nasal examination

          8. History of or current severe or uncontrolled cardiovascular, hepatic, renal and/or
             other disease/illness that could interfere w/study.

          9. History of (w/in past 12 months) or ongoing clinically relevant electrolyte
             abnormalities.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Alcon Call Center for Trial Locations</name>
      <address>
        <city>Fort Worth</city>
        <state>Texas</state>
        <zip>76134</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 13, 2008</study_first_submitted>
  <study_first_submitted_qc>October 13, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 15, 2008</study_first_posted>
  <results_first_submitted>December 3, 2009</results_first_submitted>
  <results_first_submitted_qc>January 11, 2010</results_first_submitted_qc>
  <results_first_posted type="Estimate">February 2, 2010</results_first_posted>
  <last_update_submitted>February 23, 2010</last_update_submitted>
  <last_update_submitted_qc>February 23, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 2, 2010</last_update_posted>
  <responsible_party>
    <name_title>Michael Edwards, PhD\Global Scientific Market Affairs</name_title>
    <organization>Alcon Research</organization>
  </responsible_party>
  <keyword>rhinitis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rhinitis</mesh_term>
    <mesh_term>Rhinitis, Allergic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Olopatadine Hydrochloride</mesh_term>
    <mesh_term>Azelastine</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>October 2008- November 2008</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Olopatadine 0.6% / Azelastine 137 Mcg</title>
          <description>Olopatadine 0.6% / Azelastine 137 mcg</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="102"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="102"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Olopatadine 0.6% / Azelastine 137 Mcg</title>
          <description>Olopatadine 0.6% / Azelastine 137 mcg</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="102"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="101"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Product Preference Questionnaire for Immediate Taste</title>
        <description>Using a set of coded responses, subjects evaluated product preference in regards to immediate taste</description>
        <time_frame>5 min post-dose</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Olopatadine 0.6% / Azelastine 137 Mcg</title>
            <description>Olopatadine 0.6% / Azelastine 137 mcg</description>
          </group>
        </group_list>
        <measure>
          <title>Product Preference Questionnaire for Immediate Taste</title>
          <description>Using a set of coded responses, subjects evaluated product preference in regards to immediate taste</description>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="102"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Preferred Azelastine Strongly</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26.47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Preferred Azelastine Somewhat</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.78"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Preferred Azelastine Slightly</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.88"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Same</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Preferred Olopatadine Slightly</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.82"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Preferred Olopatadine Somewhat</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.82"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Preferred Olopatadine Strongly</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23.53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Taste and Aftertaste of Medication</title>
        <time_frame>5 min, 45 min.</time_frame>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Olopatadine 0.6% / Azelastine 137 Mcg</title>
          <description>Olopatadine 0.6% / Azelastine 137 mcg</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="102"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="102"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Small sample size. The severity of symptoms experienced by patients may have masked their ability to detect taste and smell.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Alcon Clinical</name_or_title>
      <organization>Alcon Research, Ltd.</organization>
      <phone>888.451.3937; 817.568.6725</phone>
      <email>medinfo@alconlabs.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

